Skip Main Navigation
Page Content

Save This Event

Event Saved

Emerging technologies in therapeutic oligonucleotides

Annette England

Tuesday, 13 March 2018 from 09:00 to 18:00 (GMT)

Ticket Information

Type End Quantity
Emerging technologies in therapeutic oligonucleotides 12 Mar 2018 Free  

Share Emerging technologies in therapeutic oligonucleotides

Event Details

Emerging technologies in therapeutic oligonucleotides

 

MedImmune Cambridge, Tuesday 13 March 2018 

sponsored by:            GE

 

MedImmune, AstraZeneca and GE Healthcare Life Sciences, in partnership with GSK, Roche, University of Oxford, BioMax and Academy of Pharmaceutical Sciences are pleased to invite you to their sixth oligonucleotide networking event. The title of this year's event is "Emerging technologies in therapeutic oligonucleotides".  The meeting is kindly being hosted by MedImmune at their facility in Cambridge and is free to attend. There will be a networking drinks reception following the presentations, kindly sponsored by LGC Biosearch.

 

The focus of the 2018 meeting will be more in the discovery phase, with four main themes being covered throughout the day:

  • CRISPR and Axiomer technologies
  • Large molecule oligonucleotides
  • drug delivery
  • analytical and regulatory case studies

The meeting aims to bring together the community of interested professionals and practitioners in industry and academia to network, discuss the latest developments in this field, explore knowledge transfer issues and share best practise.

GE Healthcare Life Sciences offers tools and support to take oligonucleotides from research, through process development, to full-scale manufacturing. A skilled and dedicated service organization provides instrument service, technical application support, training and education through Fast Trak Design™, and professional services such as Smart Asset Management Services (SAMS) and Validation Services. www.gelifesciences.com

MedImmune is the global biologics research and development arm of AstraZeneca with candidate biologics and vaccines that currently compromise approximately 50 per cent of AstraZeneca’s overall R&D pipeline.   It has one of the most robust and promising pipelines in the biologics industry, with more than 120 biologics in research and development and over 40 projects in clinical stage development.

MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology; respiratory; and cardiovascular and metabolic disease. In addition, the company is opportunistic in infectious disease and vaccines. Approximately 2,200 full-time employees are in the US and UK. MedImmune is headquartered in Gaithersburg, MD – one of AstraZeneca’s three global R&D centres, along with Cambridge, UK and MoIndal, Sweden

MedImmune’s Cambridge team is focused on the research and early development of our biologics portfolio. MedImmune has built on the local legacy of Cambridge Antibody Technology (CAT) – acquired by AstraZeneca and integrated with MedImmune in 2007 – where three marketed products (Humira, Benlysta and raxibacumab) were invented.  With over 600 employees, MedImmune Cambridge has strong collaborative links with numerous academics, researchers, foundations and neighbouring companies in the largest biotech cluster in Europe and has an active outreach programme within the local community. www.medimmune.com


 

supported by:                     


Do you have questions about Emerging technologies in therapeutic oligonucleotides? Contact Annette England

Save This Event

Event Saved

When & Where


MedImmune
Granta Park
CB21 6GH Cambridge
United Kingdom

Tuesday, 13 March 2018 from 09:00 to 18:00 (GMT)


  Add to my calendar
Emerging technologies in therapeutic oligonucleotides
Things to do in Cambridge Networking Science & Tech

Interested in hosting your own event?

Join millions of people on Eventbrite.

Please log in or sign up

In order to purchase these tickets in installments, you'll need an Eventbrite account. Log in or sign up for a free account to continue.